Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$1.35 -3.6%	$1.44	$0.90 ▼ $3.42	$48.84M	0.87	11,411 shs	4,814 shs
ARTV Artiva Biotherapeutics	$2.03 -4.7%	$2.87	$1.78 ▼ $17.31	$49.46M	N/A	174,445 shs	168,580 shs
PHGE BiomX	$0.54 -26.9%	$0.57	$0.48 ▼ $4.90	$13.50M	1.51	80,596 shs	53,300 shs
VRCA Verrica Pharmaceuticals	$0.66 +3.2%	$0.51	$0.38 ▼ $9.40	$61.24M	1.73	583,524 shs	497,285 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	0.00%	+4.65%	+9.76%	-63.11%	-63.11%
ARTV Artiva Biotherapeutics	0.00%	-2.40%	-9.38%	-54.28%	+202,999,900.00%
PHGE BiomX	0.00%	-5.10%	+0.93%	-40.27%	-84.38%
VRCA Verrica Pharmaceuticals	0.00%	+50.52%	+35.03%	-10.11%	-92.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	1.7684 of 5 stars	3.5	3.0	0.0	0.9	1.7	0.0
ARTV Artiva Biotherapeutics	1.9962 of 5 stars	3.5	0.0	0.0	1.8	1.7	0.6
PHGE BiomX	2.1608 of 5 stars	3.5	0.0	0.0	1.9	0.8	1.3
VRCA Verrica Pharmaceuticals	4.2023 of 5 stars	3.1	2.0	4.7	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$7.00	418.52% Upside
ARTV Artiva Biotherapeutics	3.00	Buy	$19.40	855.67% Upside
PHGE BiomX	3.00	Buy	$23.00	4,159.26% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	1,107.91% Upside

Current Analyst Ratings Breakdown

Latest PHGE, ARMP, ARTV, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/9/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
4/4/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/26/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00 ➝ $18.00
3/25/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/12/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$4.53M	10.78	N/A	N/A	($0.89) per share	-1.52
ARTV Artiva Biotherapeutics	$251K	197.04	N/A	N/A	N/A	∞
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A
VRCA Verrica Pharmaceuticals	$7.57M	8.09	N/A	N/A	$0.47 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$69.04M	-$1.64	N/A	N/A	N/A	N/A	N/A	-60.91%	5/20/2025 (Estimated)
ARTV Artiva Biotherapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/23/2025 (Estimated)
PHGE BiomX	-$28.32M	-$0.85	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A
VRCA Verrica Pharmaceuticals	-$67M	-$1.54	N/A	N/A	N/A	-625.06%	-591.84%	-141.63%	N/A

Latest PHGE, ARMP, ARTV, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A
3/11/2025	Q4 2024	VRCA Verrica Pharmaceuticals	-$0.25	-$0.24	+$0.01	-$0.24	$1.30 million	$0.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.19	0.19
ARTV Artiva Biotherapeutics	N/A	11.33	11.33
PHGE BiomX	0.51	2.84	2.84
VRCA Verrica Pharmaceuticals	N/A	1.34	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
ARTV Artiva Biotherapeutics	N/A
PHGE BiomX	40.57%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	85.50%
ARTV Artiva Biotherapeutics	21.40%
PHGE BiomX	1.17%
VRCA Verrica Pharmaceuticals	42.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.18 million	5.25 million	Not Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	N/A	N/A
PHGE BiomX	120	25.00 million	44.04 million	Not Optionable
VRCA Verrica Pharmaceuticals	40	92.46 million	26.18 million	Optionable

PHGE, ARMP, ARTV, and VRCA Headlines

Recent News About These Companies

Verrica Pharmaceuticals' (VRCA) "Hold" Rating Reiterated at Needham & Company LLC

May 16 at 2:05 AM | americanbankingnews.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

Verrica Pharmaceuticals (VRCA) to Release Earnings on Tuesday

May 12, 2025 | americanbankingnews.com

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update

May 11, 2025 | msn.com

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025 | globenewswire.com

Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference

May 4, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 10, 2025 | aaii.com

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

In face of U.S. stock market selloff, shares of West Chester firm are on the rise

April 8, 2025 | bizjournals.com

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

April 8, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025 | markets.businessinsider.com

RBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)

April 5, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors

April 4, 2025 | msn.com

Verrica Pharmaceuticals Appoints Dr. Corcoran as Director

April 2, 2025 | tipranks.com

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

April 2, 2025 | globenewswire.com

Verrica Pharmaceuticals to Present at Needham Healthcare Conference

April 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, ARMP, ARTV, and VRCA Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$1.35 -0.05 (-3.57%)

As of 05/16/2025 04:10 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Artiva Biotherapeutics NASDAQ:ARTV

$2.03 -0.10 (-4.69%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$2.02 -0.01 (-0.49%)

As of 05/16/2025 07:56 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

BiomX NYSEMKT:PHGE

$0.54 -0.20 (-27.47%)

As of 05/16/2025 04:00 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.66 +0.02 (+3.19%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$0.67 +0.01 (+1.16%)

As of 05/16/2025 05:13 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time